{"entity":{"id":"nct05870800","kind":"trial","name":"Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER","aka":["NICER"],"tldr":"A phase 2 trial in colorectal cancer, run by Baylor College of Medicine, now recruiting.","summary":"Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER is a phase 2, interventional study registered as NCT05870800 by Baylor College of Medicine, with a registry enrolment figure of 28 participants, started 2025-06-15 and due to reach its primary completion in 2026-09-01. Interventions recorded: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2; Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2; Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2. Conditions listed: Stage I Colon Cancer; Stage II Colon Cancer; Stage III Colon Cancer. Primary outcome: Determine the rate of tumor regression grade 1 (<10% viable cancer cells) to neoadjuvant immunotherapy and chemotherapy in resectable (non-metastatic) pMMR colon cancer, assessed in the resection specimen.. Colorectal eligibility wording from the registry: \"* Histologically or cytologically confirmed resectable non-metastatic adenocarcinoma of the colon\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05870800","url":"https://clinicaltrials.gov/study/NCT05870800"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer","msi-high-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05870800","phase":"2","setting":"Phase II Open-label Trial of Neoadjuvant Immunotherapy (Atezolizumab) in Combination With CAPOX for Resectable Non-metastatic Proficient Mismatch Repair (pMMR) Colon CancER: NICER Study","sponsor":"Baylor College of Medicine","enrolled":28,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05870800/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}